Drug Development

Clinical Trials Therapeutics Targeted Therapy AI in Medicine Phase 3 Trials Nanotechnology AI in Healthcare Targeted Therapies Biotechnology Disease Modeling

3 ARTICLES

6d ago

Daraxonrasib Doubles Survival in Phase 3 Trial for Advanced Pancreatic Cancer

If approved, the oral pan‑RAS pill would be the first broadly active KRAS inhibitor to meaningfully extend life for most patients with metastatic pancreatic cancer.

4 ARTICLES

last wk.

MRI Reveals Long-Lasting Blood–Brain Barrier Damage in Retired Contact‑Sport Athletes

3 ARTICLES

3mo ago

Suitcase Accident Reveals Brain Tumour as 29-Year-Old Prepares for Private Treatment

3 ARTICLES

6mo ago

Sobi to Acquire Arthrosi in Up to $1.5 Billion Deal to Bolster Gout Portfolio

3 ARTICLES

6mo ago

Five Years On, AlphaFold Propels Asia-Pacific Research Breakthroughs

3 ARTICLES

7mo ago

Tohoku University Team to Launch Investigator-Led Trial of New Mitochondrial Disease Drug in December

8 ARTICLES

7mo ago

Johnson & Johnson to Buy Halda Therapeutics for $3.05 Billion to Bolster Oncology Pipeline

9 ARTICLES

8mo ago

Bristol Myers Squibb Buys Orbital Therapeutics for $1.5 Billion to Push In Vivo CAR‑T Into Autoimmune Care

3 ARTICLES

8mo ago

Scripps Team Designs Ultra-Stable Synthetic Membrane Proteins to Decode Common Folding Motif

3 ARTICLES

8mo ago

FDA Clears UCLA’s ENPP1-Blocking Antibody AD-NP1 for First-in-Human Trial

4 ARTICLES

8mo ago

Study Identifies LRP8 as the Entry Receptor for Tick-Borne Encephalitis Virus

3 ARTICLES

9mo ago

Teva Wins FDA Fast Track for Emrusolmin in Multiple System Atrophy

9 ARTICLES

9mo ago

Leqembi Launches in Germany for Early Alzheimer’s Patients

7 ARTICLES

9mo ago

CUNY Study Unveils Sugar-Targeting Compounds With Broad Antiviral Activity

Drug Development

Daraxonrasib Doubles Survival in Phase 3 Trial for Advanced Pancreatic Cancer

Eli Lilly Licenses AlzeCure’s Preclinical Alzheimer’s Candidate

NanoMesh Nanofiber Implant Doubles Survival in Mouse Glioblastoma Models

Regeneron Strikes Parabilis Deal to Develop Antibody-Helicon Drugs

Isomorphic Labs Raises $2.1 Billion to Scale AI Drug Design

OpenAI Launches GPT-Rosalind, a Biology-Tuned AI for Drug Discovery

Investor Lawsuits Target Gossamer Bio Over Failed PROSERA Trial

MRI Reveals Long-Lasting Blood–Brain Barrier Damage in Retired Contact‑Sport Athletes

Suitcase Accident Reveals Brain Tumour as 29-Year-Old Prepares for Private Treatment

Sobi to Acquire Arthrosi in Up to $1.5 Billion Deal to Bolster Gout Portfolio

Never miss stories about

Drug Development

Five Years On, AlphaFold Propels Asia-Pacific Research Breakthroughs

Tohoku University Team to Launch Investigator-Led Trial of New Mitochondrial Disease Drug in December

Johnson & Johnson to Buy Halda Therapeutics for $3.05 Billion to Bolster Oncology Pipeline

Bristol Myers Squibb Buys Orbital Therapeutics for $1.5 Billion to Push In Vivo CAR‑T Into Autoimmune Care

Scripps Team Designs Ultra-Stable Synthetic Membrane Proteins to Decode Common Folding Motif

FDA Clears UCLA’s ENPP1-Blocking Antibody AD-NP1 for First-in-Human Trial

Study Identifies LRP8 as the Entry Receptor for Tick-Borne Encephalitis Virus

Teva Wins FDA Fast Track for Emrusolmin in Multiple System Atrophy

Leqembi Launches in Germany for Early Alzheimer’s Patients

CUNY Study Unveils Sugar-Targeting Compounds With Broad Antiviral Activity

Never miss stories about

Drug Development